This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: University of Alberta. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: The Innovations of Conrad Fischer
Introduction
Conrad Fischer is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of biomedical research, particularly in the development of modified apelin polypeptides. With a total of 2 patents, Fischer's work focuses on innovative solutions for cardiovascular disorders.
Latest Patents
Fischer's latest patents include groundbreaking research on apelin peptides and their uses. The disclosures relate to modified apelin polypeptides that exhibit increased stability against kallikrein, NEP, and ACE2 degradation. These modified peptides also demonstrate enhanced potency compared to the native apelin-13 and apelin-17 polypeptides. The embodiments of these patents outline methods for utilizing these polypeptides in the treatment of cardiovascular disorders.
Career Highlights
Conrad Fischer is affiliated with the University of Alberta, where he conducts his research and development. His work has garnered attention for its potential impact on treating cardiovascular diseases, showcasing his commitment to advancing medical science.
Collaborations
Fischer collaborates with esteemed colleagues such as John C. Vederas and Shaun McKinnie. These partnerships enhance the research efforts and contribute to the innovative outcomes of their projects.
Conclusion
Conrad Fischer's contributions to the field of biomedical research, particularly through his patents on apelin peptides, highlight his role as a significant inventor. His work not only advances scientific knowledge but also holds promise for improving cardiovascular health.